IPG Investment Advisors LLC Lowers Position in Merck & Co., Inc. $MRK

IPG Investment Advisors LLC cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 82.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,702 shares of the company’s stock after selling 13,125 shares during the period. IPG Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $349,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC lifted its holdings in Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC boosted its position in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts raised price targets: HSBC lifted its target from $150 to $172 and maintained a “buy” rating, while Guggenheim raised its target to $170. Leerink Partners also increased its target from $127 to $161 and assigned an “outperform” rating. These revisions indicate continued confidence in Merck’s earnings potential and pipeline. Guggenheim Increases Merck Price Target
• Positive Sentiment: Pipeline strategy may help address Keytruda risks: Merck is pairing antibody-drug conjugates with Keytruda in women’s cancer treatments, an effort to expand its oncology franchise and offset the eventual impact of Keytruda’s patent cliff. Merck Pairs ADCs With Keytruda
• Neutral Sentiment: Investors are reassessing Merck’s valuation: A comparison with Eli Lilly highlights that Merck is trading at a higher valuation despite its slower expected growth, prompting questions about whether its pipeline, cash generation and defensive characteristics justify the premium. Merck Stock Versus Eli Lilly
• Neutral Sentiment: Market attention remains elevated: Merck was among the stocks most watched by Zacks users, suggesting strong investor interest but not necessarily a change in fundamentals. Merck Investor Attention
• Negative Sentiment: Shares declined with the broader market and underperformed during the session: The trading update provided no new company-specific catalyst, leaving valuation concerns and the Keytruda patent-cliff debate as the primary pressures on the stock.

Analyst Ratings Changes

A number of research analysts have issued reports on MRK shares. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $116.00 to $179.00 in a research note on Thursday, August 20th. Jefferies Financial Group downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a research report on Wednesday, August 12th. Finally, The Goldman Sachs Group raised their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Seventeen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $151.32.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last ninety days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $144.68 on Friday. The stock has a fifty day simple moving average of $136.22 and a two-hundred day simple moving average of $124.26. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92. The firm has a market cap of $356.96 billion, a price-to-earnings ratio of 115.75, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the business posted $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.